Outcomes in patients with hypertension and type 2 diabetes receiving a stent for angina

Aim. To study the outcomes in hypertensive (HTN) patients receiving a stent for class III angina, depending on concomitant type 2 diabetes (T2D).

Material and methods. The study included 295 patients aged 45 to 75 years. All patients underwent coronary angiography followed by elective stenting. Clinical outcomes were evaluated after outpatient follow-up (average 44 months). Patients were divided into two groups: group 1 — 214 patients with coronary artery disease (CAD) in combination with HTN; group 2 — 81 patients with CAD in combination with HTN and T2D.

Results.In the group of patients without T2D, during the follow-up period, class III angina was observed in 92 patients (43%). The decrease in systolic blood pressure (BP) (SBP) and diastolic BP (DBP) in this subgroup was 18 and 14 mm Hg, respectively (p<0,001); 35 patients (38%) had myocardial infarction (MI). In the group of patients with T2D, class III angina was recorded in 60 patients (74,1%). The decrease in SBP and DBP in this subgroup was 19 and 12 mm Hg, respectively  (p<0,001). There were 58 cases of MI in this subgroup (96,7%).

Conclusion.After stent insertion, patients with CAD, HTN and T2D still reporting class III angina were more likely to have MI than patients without T2D. This indicates a greater contribution of T2D to MI development, despite an equal decrease of SBP in patients with/without T2D.

1. Vidal-Petiot E, Ford I, Greenlaw N et al. CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016; 388: 2142–2152. doi.org/10.1016/S0140-6736(16)31326-5.

2. Cosentino F, Grant P, Aboyans V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2019; 00: 1-69. doi:10.1093/eurheartj/ehz486.

3. Das S, Everett B, Birtcher K et al. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JACC 2018; 24: 3200–3023. doi.org/10.1016/j.jacc.2018.09.020.

4. Safar M, Gnakaméné J-B, Bahous S et al. Longitudinal Study of Hypertensive Subjects With Type 2 Diabetes Mellitus. Overall and Cardiovascular Risk. Hypertension. 2017; 69: 1029-1035. doi: 10.1161/HYPERTENSIONAHA.116.08962.

5. Rana J, Dunning A, Achenbach S et al. Differences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes undergoing coronary computed tomography angiography: results from 10,110 individuals from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes): an international multicenter registry. Diabetes Care 2012; 35: 1787–94. doi.org/10.2337/dc11-2403.

6. La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. European Journal of Preventive Cardiology 2019; 26 (2S): 15–24. doi: 10.1177/2047487319878373.

7. Grodzinsky A, Kosiborod M, Tang T et al. Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2017;10: e003553. doi: 10.1161/CIRCOUTCOMES.117.003553.